fbpx

Clinical Studies

Alzheimer’s and Memory Loss Clinical Studies

Have you been diagnosed with Alzheimer’s ? Do you want to partner in the kind of research that can give your grandchildren greater access to more effective treatment options? Maybe you’d like to be a part of finding a cure?

We’re partnering with patients like you on groundbreaking research to help doctors and caregivers treat and care for those affected by Alzheimer’s disease today, as well as those who come after us.

We’d love to partner with you.

Do I qualify?

Each clinical study has its own set of criteria that a patient must meet in order to participate. The first step to find out if you or a loved one qualifies is to schedule a prescreen interview with one of our team members.

Types of Studies

What studies are available?

Below you’ll find the clinical trials that we’re currently enrolling patients in or will be soon.

View All Open Studies

Schedule a Prescreen

“AHEAD” Alzheimer’s Prevention
If you're worried that your memory might start fading, then joining an Alzheimer's prevention study might be a great option for you. It might just help future generations too. This study examines whether a new drug may help to slow or prevent the onset of Alzheimer's disease in those with elevated risk of developing the disease.
Tau Protein “PET” Detection Study
The purpose of this study is to investigate the effectiveness and safety of a new injection—given in conjunction with a PET scan—to help detect tau protein in the brain. Early detection could help with the diagnostic process, as well as the treatment of, Alzheimer's disease.
Amyloid Plaque “AbbVie” Alzheimer’s Study
Amyloid plaques in the brain may be the main cause of Alzheimer's disease. This study is to determine if a new drug can reduce amyloid plaques and slow disease progression.
AriBio Early Alzheimer’s Trial
The purpose of this study is to find out if the study drug, called AR1001, can help people with Alzheimer’s Disease. Some research has shown that people with Alzheimer’s Disease have damage to the blood vessels in their brain. It is thought that AR1001 may help the blood vessels in your brain work better.
GAP “Apheleia” Alzheimer’s Identification Study
This short study aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and a blood test to distinguish appropriate participants for referral to a therapeutic Alzheimer's clinical trial.
“Cohort” Alzheimer’s Study
The goal of this study is to build a large group, or “cohort”, of individuals who are interested in being recruited into Alzheimer's dementia clinical trials. We will collect data from cognitively normal or minimally-impaired individuals and then inform them if a trial may be appropriate.
Sensory Stimulation Alzheimer’s “Hope” Study
The main purpose of this study is to see whether daily use of a device called the "Sensory Stimulation System" can help people with Alzheimer's-related memory problems. The device provides sensory stimulation via glasses worn on the face and headphones worn over the ears.
“Avanir” Alzheimer’s Agitation Trial
This study evaluates a new medication to treat agitation in people with Alzheimer's disease. It is hoped this potential treatment could reduce caregiver burden and improve overall disease prognosis.
Protein Inhibitor “Annovis” Alzheimer’s Study
A research study of a drug called buntanetap under development for the treatment of Alzheimer’s disease, possibly improving cognition in patients by inhibiting neurotoxic proteins.
“CELIA” Alzheimer’s Trial
This study tests a new investigational medication for the treatment of Alzheimer's disease.  The drug is hoped to work by targeting and preventing the accumulation of tau tangles.
Combination Therapy “CuraSen” Trial
The goal of the study is to evaluate the effects of a novel combination therapy on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.
“Merck” Early Alzheimer’s Disease Trial
In this trial, an investigational drug is used to target tau proteins to reduce or stop their spread and slow the progression of Alzheimer's disease.
“ENVISION” Alzheimer’s Trial
This study tests the FDA-approved medication Aduhelm. The trial is designed to verify the drug's efficacy in reducing amyloid plaques and slowing the rate of cognitive decline.

Commitment to Your Care

Who will I be working with?

Participating in a clinical trial can feel intimidating at first. Put your mind at ease by getting to know some of our caring experts who’ll be working with you every step of the way.

Learn more about our Commitment to Care

Jeffrey Norton, MD
Medical Director, The Villages
Leading our research center in The Villages, Florida, Dr. Jeffrey Norton has more than 20 years of experience in anesthesiology and pain management and has served...
Edgardo Rivera, MD, FACEP
Medical Director, Winter Park
Leading our research center in Winter Park, Florida, Dr. Edgardo Rivera has served as Principal Investigator or Sub-Investigator on more than 40 clinical trials across...
Diana Balsalobre, MD
Principal Investigator
Dr. Diana Balsalobre is a Board-Certified Neurologist with over 22 years of clinical experience.  She completed her Internship and Neurology Residency in Jackson Memorial Hospital...
Stephen Miller, MD
Principal Investigator
Dr. Stephen Miller has over 15 years of diverse clinical and healthcare policy experience and has served as an investigator on more than 20 clinical...
Mary Quarterman, MD
Principal Investigator
Dr. Mary Quarterman is an established and highly skilled physician with over 13 years of experience.  Dr. Quarterman received her medical degree from Florida State...
Ramon Rodriguez, MD
Principal Investigator
Dr. Ramon Rodriguez is a board certified Neurologist and highly experienced Principal Investigator. Dr. Rodriguez received his medical degree (M.D.) from the University of Puerto...

Our Promise to You

What resources do you have for me?

We regularly share insights, tips, and new discoveries to provide you the latest on the diseases and chronic conditions you’re living with.

See all resources

Can You Reverse Mild Cognitive Impairment?
Nearly one in five Americans over the age of 60 experience subtle downturns in memory, thinking, and cognition. Clinically, this fading of cognitive abilities is...
The lesser-known problematic protein wreaking havoc on the brain: TDP-43
Scientists have linked the progression of Alzheimer’s to the buildup of certain kinds of protein in the brain, which malfunction and gum up communication between...
Could Drugs for Other Diseases Be the Answer to Treating Alzheimer’s?
Asthma drugs, cancer drugs, even obesity drugs, are all being explored for their potential in treating the pathology and symptoms of Alzheimer’s disease. Finding the...
Why Women Are More Likely to Develop Alzheimer’s
Research has established that women are twice as likely to develop Alzheimer’s, but despite study after study into this sex-based disparity in Alzheimer’s risk, scientists...
Managing Symptoms in the Later Stages of Alzheimer’s
Symptom management in Alzheimer’s helps people remain independent for longer. Alzheimer’s disease is a progressive neurodegenerative condition that affects more than one in every 9...
A Pill For Alzheimer’s? Alzheon Starts Clinical Trials
Charter Research is recruiting for a new Phase 3 trial for Alzheon’s new drug, which aims to be the first oral disease-modifying therapy for Alzheimer’s....

Sign up to receive new Alzheimers research and resources.

Let us come to you. Sign up for our newsletter, and we’ll send updates right to your inbox.

Your information

This field is for validation purposes and should be left unchanged.